Fortitude Family Office LLC Has $468,000 Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Fortitude Family Office LLC boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,977 shares of the medical research company’s stock after acquiring an additional 56 shares during the period. Fortitude Family Office LLC’s holdings in IQVIA were worth $468,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of IQV. Versant Capital Management Inc lifted its position in shares of IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA during the second quarter worth approximately $27,000. Park Place Capital Corp bought a new stake in shares of IQVIA in the third quarter valued at approximately $28,000. Itau Unibanco Holding S.A. acquired a new stake in shares of IQVIA in the second quarter worth $29,000. Finally, International Assets Investment Management LLC bought a new position in IQVIA during the second quarter worth $32,000. 89.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

IQV has been the topic of several research analyst reports. Jefferies Financial Group lowered shares of IQVIA from a “buy” rating to a “hold” rating and decreased their price target for the stock from $266.00 to $242.00 in a research report on Wednesday, July 24th. Royal Bank of Canada initiated coverage on IQVIA in a research note on Wednesday, September 4th. They set an “outperform” rating and a $275.00 price target on the stock. Truist Financial cut their price target on IQVIA from $300.00 to $286.00 and set a “buy” rating for the company in a report on Monday, October 14th. Barclays decreased their price objective on IQVIA from $275.00 to $260.00 and set an “overweight” rating on the stock in a report on Tuesday, October 15th. Finally, Argus raised IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $267.27.

IQVIA Price Performance

Shares of IQVIA stock opened at $217.54 on Tuesday. The stock has a market capitalization of $39.66 billion, a price-to-earnings ratio of 28.25, a P/E/G ratio of 2.09 and a beta of 1.49. The firm’s 50-day moving average price is $237.12 and its two-hundred day moving average price is $230.29. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.